Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Arsenic + ATRA in Newly Diagnosed APL (IC-APL2020)
NCT06982274Phase 2Recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Oct 2023
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Compound Huangdai Tablet in acute promyelocytic leukemia (APL), sponsored by Instituto do Câncer do Estado de São Paulo. Started Oct 2023; status: recruiting.
02
Drugs
Compound Huangdai Tablet
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT06982274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982274.